{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T19:05:44Z","timestamp":1792868744449,"version":"4.5.0"},"reference-count":28,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2020,12,8]],"date-time":"2020-12-08T00:00:00Z","timestamp":1607385600000},"content-version":"unspecified","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Assistance Publique - H\u00f4pitaux de Marseille","id":[{"id":"https:\/\/ror.org\/00pg5jh14","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003100","name":"F\u00e9d\u00e9ration Fran\u00e7aise de Cardiologie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003100","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004099","name":"Ligue Contre le Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004099","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2020,11,20]]},"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Myocarditis is a rare but life-threatening adverse event of cancer treatments with immune checkpoint inhibitors (ICIs). Recent guidelines recommend the use of high doses of corticosteroids as a first-line treatment, followed by intensified immunosuppressive therapy (IIST) in the case of unfavorable evolution. However, this strategy is empirical, and no studies have specifically addressed this issue. Therefore, we aimed to investigate and compare the clinical course, management and outcome of ICI-induced myocarditis patients requiring or not requiring IIST.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This case\u2013control study included all patients consecutively admitted to The Mediterranean University Center of Cardio-Oncology (Aix-Marseille University, France) for the diagnosis of ICI-induced myocarditis according to Bonaca\u2019s criteria and treated with or without IIST. In addition, we searched PubMed and included patients from previously published case reports treated with IIST in the analysis. The clinical, biological, imaging, treatment, all-cause death and cardiovascular death data of patients who required IIST were compared with those of patients who did not.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 60 patients (69\u00b112 years) were included (36 were treated with IIST and 24 were not). Patients requiring IIST were more likely to have received a combination of ICIs (39% vs 8%, p=0.01), and developed the first symptoms\/signs of myocarditis earlier after the onset of ICI therapy (median, 18 days vs 60 days, p=0.002). They had a significantly higher prevalence of sustained ventricular arrhythmia, complete atrioventricular block, cardiogenic shock and troponin elevation. Moreover, they were more likely to have other immune-related adverse events simultaneously (p&lt;0.0001), especially myositis (p=0.0002) and myasthenia gravis (p=0.009). Patients who required IIST were more likely to die from any cause (50% vs 21%, p=0.02). Among them, patients who received infliximab were more likely to die from cardiovascular causes (OR, 12.0; 95% CI 2.1 to 67.1; p=0.005).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The need for IIST was more common in patients who developed myocarditis very early after the start of ICI therapy, as well as when hemodynamic\/electrical instability or neuromuscular adverse events occurred. Treatment with infliximab might be associated with an increased risk of cardiovascular death.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2020-001887","type":"journal-article","created":{"date-parts":[[2020,12,9]],"date-time":"2020-12-09T00:51:19Z","timestamp":1607475079000},"page":"e001887","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":95,"title":["Intensified immunosuppressive therapy in patients with immune checkpoint inhibitor-induced myocarditis"],"prefix":"10.1136","volume":"8","author":[{"given":"Jennifer","family":"Cautela","sequence":"first","affiliation":[{"name":"University Mediterranean Centre of Cardio-Oncology (MEDI-CO centre), Unit of Heart Failure and Valvular Heart Diseases, Department of Cardiology, Nord Hospital, Centre for CardioVascular and Nutrition research (C2VN), INSERM 1263, INRAE 1260, Aix-Marseille University, Assistance Publique \u2013 H\u00f4pitaux de Marseille, Marseille, Provence-Alpes-C\u00f4te d'Azur, France"},{"name":"Mediterranean Group of Cardio-oncology (gMEDICO), Aix-Marseille-University, Marseille, Provence-Alpes-C\u00f4te d'Azur, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Zeriouh","sequence":"additional","affiliation":[{"name":"University Mediterranean Centre of Cardio-Oncology (MEDI-CO centre), Unit of Heart Failure and Valvular Heart Diseases, Department of Cardiology, Nord Hospital, Centre for CardioVascular and Nutrition research (C2VN), INSERM 1263, INRAE 1260, Aix-Marseille University, Assistance Publique \u2013 H\u00f4pitaux de Marseille, Marseille, Provence-Alpes-C\u00f4te d'Azur, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Gaubert","sequence":"additional","affiliation":[{"name":"University Mediterranean Centre of Cardio-Oncology (MEDI-CO centre), Unit of Heart Failure and Valvular Heart Diseases, Department of Cardiology, Nord Hospital, Centre for CardioVascular and Nutrition research (C2VN), INSERM 1263, INRAE 1260, Aix-Marseille University, Assistance Publique \u2013 H\u00f4pitaux de Marseille, Marseille, Provence-Alpes-C\u00f4te d'Azur, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Bonello","sequence":"additional","affiliation":[{"name":"University Mediterranean Centre of Cardio-Oncology (MEDI-CO centre), Unit of Heart Failure and Valvular Heart Diseases, Department of Cardiology, Nord Hospital, Centre for CardioVascular and Nutrition research (C2VN), INSERM 1263, INRAE 1260, Aix-Marseille University, Assistance Publique \u2013 H\u00f4pitaux de Marseille, Marseille, Provence-Alpes-C\u00f4te d'Azur, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Laine","sequence":"additional","affiliation":[{"name":"University Mediterranean Centre of Cardio-Oncology (MEDI-CO centre), Unit of Heart Failure and Valvular Heart Diseases, Department of Cardiology, Nord Hospital, Centre for CardioVascular and Nutrition research (C2VN), INSERM 1263, INRAE 1260, Aix-Marseille University, Assistance Publique \u2013 H\u00f4pitaux de Marseille, Marseille, Provence-Alpes-C\u00f4te d'Azur, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Peyrol","sequence":"additional","affiliation":[{"name":"University Mediterranean Centre of Cardio-Oncology (MEDI-CO centre), Unit of Heart Failure and Valvular Heart Diseases, Department of Cardiology, Nord Hospital, Centre for CardioVascular and Nutrition research (C2VN), INSERM 1263, INRAE 1260, Aix-Marseille University, Assistance Publique \u2013 H\u00f4pitaux de Marseille, Marseille, Provence-Alpes-C\u00f4te d'Azur, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Paganelli","sequence":"additional","affiliation":[{"name":"University Mediterranean Centre of Cardio-Oncology (MEDI-CO centre), Unit of Heart Failure and Valvular Heart Diseases, Department of Cardiology, Nord Hospital, Centre for CardioVascular and Nutrition research (C2VN), INSERM 1263, INRAE 1260, Aix-Marseille University, Assistance Publique \u2013 H\u00f4pitaux de Marseille, Marseille, Provence-Alpes-C\u00f4te d'Azur, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Lalevee","sequence":"additional","affiliation":[{"name":"University Mediterranean Centre of Cardio-Oncology (MEDI-CO centre), Unit of Heart Failure and Valvular Heart Diseases, Department of Cardiology, Nord Hospital, Centre for CardioVascular and Nutrition research (C2VN), INSERM 1263, INRAE 1260, Aix-Marseille University, Assistance Publique \u2013 H\u00f4pitaux de Marseille, Marseille, Provence-Alpes-C\u00f4te d'Azur, France"},{"name":"Technological Advances for Genomics and Clinics (TAGC), UMR\/INSERM 1090, Aix-Marseille-University, Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Barlesi","sequence":"additional","affiliation":[{"name":"Mediterranean Group of Cardio-oncology (gMEDICO), Aix-Marseille-University, Marseille, Provence-Alpes-C\u00f4te d'Azur, France"},{"name":"Gustave Roussy, Drug Development Department (DITEP), Paris-Saclay University, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8727-7154","authenticated-orcid":false,"given":"Franck","family":"Thuny","sequence":"additional","affiliation":[{"name":"University Mediterranean Centre of Cardio-Oncology (MEDI-CO centre), Unit of Heart Failure and Valvular Heart Diseases, Department of Cardiology, Nord Hospital, Centre for CardioVascular and Nutrition research (C2VN), INSERM 1263, INRAE 1260, Aix-Marseille University, Assistance Publique \u2013 H\u00f4pitaux de Marseille, Marseille, Provence-Alpes-C\u00f4te d'Azur, France"},{"name":"Mediterranean Group of Cardio-oncology (gMEDICO), Aix-Marseille-University, Marseille, Provence-Alpes-C\u00f4te d'Azur, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,12,8]]},"reference":[{"key":"2025100306240983000_8.2.e001887.1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar4060"},{"key":"2025100306240983000_8.2.e001887.2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv623"},{"key":"2025100306240983000_8.2.e001887.3","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1001\/jamacardio.2017.0119","article-title":"Potential of Oncocardiology","volume":"2","author":"Cautela","year":"2017","journal-title":"JAMA Cardiol"},{"key":"2025100306240983000_8.2.e001887.4","first-page":"476","article-title":"Acute coronary syndrome with immune checkpoint inhibitors: a proof-of-concept case and pharmacovigilance analysis of a life-threatening adverse event","volume":"36","author":"Cautela","year":"2020","journal-title":"Can J Cardiol"},{"key":"2025100306240983000_8.2.e001887.5","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30608-9"},{"key":"2025100306240983000_8.2.e001887.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609214"},{"key":"2025100306240983000_8.2.e001887.7","doi-asserted-by":"crossref","first-page":"e447","DOI":"10.1016\/S1470-2045(18)30457-1","article-title":"Immune checkpoint inhibitors and cardiovascular toxicity","volume":"19","author":"Lyon","year":"2018","journal-title":"Lancet Oncol"},{"key":"2025100306240983000_8.2.e001887.8","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.117.030571"},{"key":"2025100306240983000_8.2.e001887.9","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"2025100306240983000_8.2.e001887.10","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/CJI.0000000000000239","article-title":"Autoimmune myocarditis caused by immune checkpoint inhibitors treated with antithymocyte globulin","volume":"41","author":"Jain","year":"2018","journal-title":"J Immunother"},{"key":"2025100306240983000_8.2.e001887.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.02.037"},{"key":"2025100306240983000_8.2.e001887.12","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1093\/cvr\/cvz026","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors","volume":"115","author":"Hu","year":"2019","journal-title":"Cardiovasc Res"},{"key":"2025100306240983000_8.2.e001887.13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6385"},{"key":"2025100306240983000_8.2.e001887.14","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx225"},{"key":"2025100306240983000_8.2.e001887.15","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.018403","article-title":"Cardiovascular toxicity related to cancer treatment: a pragmatic approach to the American and European Cardio-Oncology guidelines","volume":"9","author":"Alexandre","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"2025100306240983000_8.2.e001887.16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1901677"},{"key":"2025100306240983000_8.2.e001887.17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1903064"},{"key":"2025100306240983000_8.2.e001887.18","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1016\/j.jtho.2019.09.080","article-title":"Tocilizumab for fulminant programmed death 1 inhibitor-associated myocarditis","volume":"15","author":"Wang","year":"2020","journal-title":"J Thorac Oncol"},{"key":"2025100306240983000_8.2.e001887.19","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1161\/CIRCULATIONAHA.118.034497","article-title":"Myocarditis in the setting of cancer therapeutics: proposed case definitions for emerging clinical syndromes in Cardio-Oncology","volume":"140","author":"Bonaca","year":"2019","journal-title":"Circulation"},{"key":"2025100306240983000_8.2.e001887.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.09.072"},{"key":"2025100306240983000_8.2.e001887.21","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30533-6"},{"key":"2025100306240983000_8.2.e001887.22","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1161\/CIRCULATIONAHA.119.044703","article-title":"Major adverse cardiovascular events and the timing and dose of corticosteroids in immune checkpoint Inhibitor\u2013Associated myocarditis","volume":"141","author":"Zhang","year":"2020","journal-title":"Circulation"},{"key":"2025100306240983000_8.2.e001887.23","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1111\/bcp.14433","article-title":"Evolving insights into the mechanisms of toxicity associated with immune checkpoint inhibitor therapy","author":"Mangan","year":"2020","journal-title":"Br J Clin Pharmacol"},{"key":"2025100306240983000_8.2.e001887.24","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxs098"},{"key":"2025100306240983000_8.2.e001887.25","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(01)01299-2"},{"key":"2025100306240983000_8.2.e001887.26","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000017216.41471.DF"},{"key":"2025100306240983000_8.2.e001887.27","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-138-10-200305200-00008"},{"key":"2025100306240983000_8.2.e001887.28","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1002\/ibd.21546","article-title":"Myocarditis associated with infliximab: a case report and review of the literature","volume":"17","author":"Slattery","year":"2011","journal-title":"Inflamm Bowel Dis"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2020-001887","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T13:24:22Z","timestamp":1759497862000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2020-001887"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":28,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,12,8]]},"published-print":{"date-parts":[[2020,12]]}},"alternative-id":["10.1136\/jitc-2020-001887"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2020-001887","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12]]}}}